Document is current
Any future updates will be listed below
-
Authors
Elliehausen, Christian J.
Anderson, Rozalyn M.
Diffee, Gary M.
Rhoads, Timothy W.
Lamming, Dudley W.
Hornberger, Troy A.
Konopka, Adam R. http://orcid.org/0000-0001-6655-6747
-
Funding
Funding for this research was provided by:
American Federation for Aging Research (#A22001)
National Institute on Aging (U01-AG081482, U01-AG076941, R21-AG067464, AG056771, AG081482, AG067330, AG074503)
National Institute of Arthritis and Musculoskeletal and Skin Diseases (R56-AR05734)
National Institute of Diabetes and Digestive and Kidney Diseases (DK125859)
- License Information
-
More Information
Article History
Received: 5 July 2023
Accepted: 23 November 2023
First Online: 8 December 2023
Declarations
:
: D.W.L has received funding from, and is a scientific advisory board member of, Aeovian Pharmaceuticals, which seeks to develop novel, selective mTOR inhibitors for the treatment of various diseases.
